NCT03600883: A Phase 1/2, Study Evaluating the Safety, Tolerability, PK, and Efficacy of AMG 510 in Subjects With Solid Tumors With a Specific KRAS Mutation.

NCT03600883
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: KRAS+
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 1
Drug Category: Tyrosine-Kinase Inhibitor

Key Eligibility Criteria:

Gender: All
Age: 18 Years to 100 Years (Adult, Older Adult)
Location of Metastases: 
Additional Notes: Patients must have KRAS p.G12C mutation identified through DNA sequencing to be eligible for the dose expansion phase
Exclusions: Patients with active brain metastases
https://ClinicalTrials.gov/show/NCT03600883

Comments are closed.

Up ↑